Merck Sharp & Dohme 10-Q2004 Q2 Quarterly report

Filed: 6 Aug 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acetaminophen, adjunctive, Adult, advanced, Advisory, antibody, approvedVytorinfor, area, asZocorfor, ATP, attempting, augment, Aurora, Australia, avoid, awaiting, Bank, benign, blocking, brandedInegyin, category, chairman, chart, Chase, chickenpox, codeine, Columbia, comparison, Conference, cooperating, Daley, Demand, diagnosed, disorder, distinct, distraction, Division, drugVioxx, Education, endorsed, enlargement, ensure, EPO, exposure, extend, extended, Fee, forArcoxiaat, foregoing, forFosamaxwere, formal, forProQuadin, forRotaTeqin, forVioxxdecreased, forVioxxto, Fosamaxcontinued, France, gave, glaucoma, GLP, goal, Good, Harrison, healthy, Heidi, hypercholesterolemia, hyperlipidemia, ibuprofen, Immunization, implicated, Inspector, JP, Jr, kinase, Laboratory, large, launchVytorinin, line, lt, lumbar, Lung, Maryland, Medicare, merger, Miller, Modernization, Morgan, multiple, naproxen, narcotic, NCEP, notablyPrilosecandNexium, notification, ofFosamaxOnce, ofProQuadin, ofZocor, onset, optimal, osteopenia, pandemic, paragraph, PDUFA, pentavalent, PLA, play, political, Preclinical, prejudice, prostate, protracted, recommended, recommending, rely, rendered, repurchase, resigned, resolved, REST, Retirement, revoke, routinely, safety, Security, shortened, shown, sodium, Spain, subsidy, test, thatFosamaxprovided, told, toVioxxmay, tumor, typically, unmet, User, Vertex, Virginia, William, withArcoxiawere, withdrawn, Zealand

Removed: achieved, active, bleeding, brand, California, controller, coordinated, damage, decreased, dividend, drove, Ezetrol, gastrointestinal, inventory, judge, kidney, maintained, Nexium, nondeductibility, notably, Prilosec, reduce, stroke, transferred, wholly, Zocor

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Merck Sharp & Dohme similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Section 1350
Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 6, 2004		/s/ Raymond V. Gilmartin

	Name:	Raymond V. Gilmartin
	Title:	Chairman, President and Chief Executive Officer